US generic drug spending declined by $5.5bn in 2017 driven by pricing pressure, according to a new US drug spending report released by the IQVIA Institute for Human Data Science April 19.
"Generic growth had been a positive driver of growth from 2013-2015 as the combination of fewer expiries and price increases lifted spending," the IQVIA report says. "Growth slowed in 2016...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?